MedTrace Logo

The Effect of YJ001 on Diabetic Peripheral Neuropathic Pain.

NCT04953221 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 225

Last updated 2021-07-07

No results posted yet for this study

Summary

In this study, a randomized, double-blind, placebo parallel-controlled design was used to evaluate the effectiveness and safety of YJ001 spray applied to local skin in patients with diabetic peripheral neuropathic pain, and to explore the best effective dose.

Conditions

  • Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

YJ001

Skin spray

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-07-01
Completion
2023-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04953221 on ClinicalTrials.gov